Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™GlobeNewsWire • 11/18/24
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in EuropeZacks Investment Research • 11/15/24
Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drugMarket Watch • 11/14/24
Biogen (BIIB) Loses -6.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 11/04/24
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) ConferenceGlobeNewsWire • 10/30/24
Biogen Earnings Top Views; Alzheimer's Drug Leqembi Gaining MomentumInvestors Business Daily • 10/30/24
Biogen tops estimates, raises profit guidance as Alzheimer's drug Leqembi gains tractionCNBC • 10/30/24
Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer's, Rare, and Immunological DiseasesGlobeNewsWire • 10/29/24
Seeking Clues to Biogen (BIIB) Q3 Earnings? A Peek Into Wall Street Projections for Key MetricsZacks Investment Research • 10/28/24
Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024GlobeNewsWire • 10/27/24